Arca
Skip to content
Tools
Tools

CNR1: Cannabinoid receptor 1

A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.

G protein-coupled receptor for endogenous cannabinoids (eCBs), including N-arachidonoylethanolamide (also called anandamide or AEA) and 2-arachidonoylglycerol (2-AG), as well as phytocannabinoids, such as delta(9)-tetrahydrocannabinol (THC).

  • Drugs that act on it: 13
  • Approved: 4
  • In phases 1 to 3: 9
  • Sponsors: 10

Who Is On It, and How Far Along

Every drug ChEMBL records acting on CNR1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule
  • Antibody

Approved4

  • Cannabidiol
  • Dronabinol
  • Rimonabant
  • Nabilone

Phase 33

  • Drinabant
  • Otenabant
  • Taranabant

Phase 25

  • Nimacimab
  • AZD2207
  • Ibipinabant
  • Nonabine
  • Surinabant

Phase 11

  • SAD448

Sponsors

Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.

Modalities

Drugs on this target by ChEMBL molecule type.

  • Small molecule1292%
  • Antibody18%

The Landscape

Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
CannabidiolApprovedJazz PharmaceuticalsSmall moleculeNegative allosteric modulatorCannabinoid CB1 receptor negative allosteric modulator146—
DronabinolApprovedAlkem LaboratoriesSmall moleculeAgonistCannabinoid CB1 receptor agonist85—
RimonabantApprovedSinfatin S.LSmall moleculeAntagonistCannabinoid CB1 receptor antagonist4Withdrawn
NabiloneApprovedBausch HealthSmall moleculeAgonistCannabinoid CB1 receptor agonist2—
DrinabantPhase 3SanofiSmall moleculeAntagonistCannabinoid CB1 receptor antagonist0—
OtenabantPhase 3PfizerSmall moleculeAntagonistCannabinoid CB1 receptor antagonist0—
TaranabantPhase 3Merck & Co. (MSD)Small moleculeInverse agonistCannabinoid CB1 receptor inverse agonist0—
NimacimabPhase 2Skye Bioscience, Inc.AntibodyNegative allosteric modulatorCannabinoid CB1 receptor negative allosteric modulator1—
AZD2207Phase 2—Small moleculeAntagonistCannabinoid CB1 receptor antagonist0—
IbipinabantPhase 2Bristol-Myers SquibbSmall moleculeAntagonistCannabinoid CB1 receptor antagonist0—
NonabinePhase 2—Small moleculeAgonistCannabinoid CB1 receptor agonist0—
SurinabantPhase 2SanofiSmall moleculeAntagonistCannabinoid CB1 receptor antagonist0—
SAD448Phase 1Novartis PharmaceuticalsSmall moleculeAgonistCannabinoid CB1 receptor agonist0—

Open Trials

The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 20 in all, from ClinicalTrials.gov.
Study of the Effects of Rimonabant on Functional Recovery in Subacute Stroke PatientsRimonabantPhase 2Not yet recruitingSinfatin S.L2026-11-17
Efficacy of Vaped Cannabidiol in Cannabis Use DisorderCannabidiolNot applicableNot yet recruitingUniversity Hospital, Bordeaux2026-11-12
Rimonabant for Cognitive Impairment in People With Post-COVID-19 SyndromeRimonabantPhase 2Not yet recruitingSinfatin S.L2026-11-12
A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy AdultsCannabidiolPhase 1Not yet recruitingAvata Biosciences Holdings Ltd2026-11-05
Rimonabant for Improving Walking Ability in Patients With Chronic StrokeRimonabantPhase 2Not yet recruitingSinfatin S.L2026-11-03
Effects of Cannabidiol on Memory and Attention in Adults Aged 60-70: A Pilot StudyCannabidiolNot applicableNot yet recruitingMedical University of Silesia2026-11-02
Cannabidiol in Opioid Use Disorder and Chronic Pain With BuprenorphineCannabidiolEarly phase 1RecruitingYale University2026-10-21
An Investigation of Mechanisms That Underly Paranoia in Behaviour and Brain That Can Inform Clinical Diagnoses That Include Paranoid Symptoms.DronabinolPhase 2Not yet recruitingKing's College London2026-10-16
Effects of Cannabidiol (CBD) on a Fixed Dose of Delta-9-tetrahydrocannabinol (THC)Cannabidiol, DronabinolPhase 1Not yet recruitingJohns Hopkins University2026-10-13
Effect of Rimonabant on Hand Function in Patients With Spinal Cord InjuryRimonabantPhase 1 / Phase 2Active, not recruitingSinfatin S.L2026-09-25
Oral and Topical Phytocannabinoids for PsoriasisCannabidiol, DronabinolPhase 2Active, not recruitingFederal University of Latin American Integration2026-09-24
CannaRiver CBD Calm for Anxiety, Sleep, and Well-Being in Adults With Generalized Anxiety DisorderCannabidiolNot applicableNot yet recruitingAssociação Pan-Americana Multidisciplinar de Endocanabinologia2026-09-16
Endocannabinoids in RewardDronabinolPhase 2RecruitingMedical University of South Carolina2026-09-11
Full-Spectrum Cannabis Extract for Chronic Pain and Bone Health Biomarkers in WomenCannabidiol, DronabinolPhase 2Not yet recruitingAssociação Pan-Americana Multidisciplinar de Endocanabinologia2026-08-24
Lung Health and Breath Biomarkers: Acute Effects of Inhaled CannabisDronabinolEarly phase 1Not yet recruitingHannah Harris2026-07-10
Cannabidiol Oil for Treatment-Resistant Major DepressionDronabinolPhase 1 / Phase 2RecruitingUniversidade do Sul de Santa Catarina2026-07-10
Challenging the Endocannabinoid System in Sleep Restricted Healthy Volunteers to Modulate Physiological Arousal (CANISLEEP) StudyDronabinolNot applicableRecruitingKing's College London2026-06-18
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderNabilonePhase 3RecruitingPleoPharma, Inc.2026-06-12
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs PlaceboNimacimabPhase 2Active, not recruitingSkye Bioscience, Inc.2024-08-29
Nabilone for Agitation Blinded Intervention TrialNabilonePhase 3RecruitingSunnybrook Health Sciences Centre2020-08-17

Diseases Most Associated With It

Open Targets association score, 0 to 1; all associations
Obesity disorder
0.64
Seizure
0.52
Cancer
0.50
Encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy
0.50
Nausea
0.50
Type 2 diabetes mellitus
0.42

Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL218, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P21554, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.